Cancer transcriptomes frequently exhibit RNA dysregulation. As the resulting aberrant
transcripts may be translated into cancer-specific proteins, there is growing interest in …

Cancer is a heterogeneous and complex disease. Tumors are formed by cancer cells and a
myriad of non-cancerous cell types that together with the extracellular matrix form the tumor …

Immunotherapies such as immune checkpoint blockade and adoptive cell transfer have
revolutionized cancer treatment, but further progress is hindered by our limited …

Transcriptomics, which encompasses assessments of alternative splicing and alternative
polyadenylation, identification of fusion transcripts, explorations of noncoding RNAs …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan …

RNA sequencing (RNA-seq) provides an efficient high-throughput technique to robustly
characterize the tumor immune microenvironment (TME). The increasing use of RNA-seq in …

Immunotherapies targeting cancer-specific neoantigens have revolutionized the treatment of
cancer patients. Recent evidence suggests that epigenetic therapies synergize with …

Immune system gene regulation perturbation has been found to be a major cause of the
development of various types of cancer. Numbers of mechanisms contribute to gene …

A core mission of cancer genomics is to comprehensively chart molecular underpinnings of
cancer-driving events and to provide personalized therapeutic strategies. Primarily focused …

Evolving neoplasms accumulate non-synonymous mutations at a high rate, potentially
enabling the expression of antigenic epitopes that can be recognized by the immune …